ArticlePediatric rheumatology online journal2025
Clinical characteristics and treatment of infantile Takayasu arteritis in the Chinese Han population: a single-center study.
Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Refractory Kawasaki Disease in Infants Complicated with Giant Coronary Artery Aneurysms and Takayasu Arteritis: A Rare Case Report and Literature Review.Vascular health and risk management · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesThis study aims to summarize and explore the clinical characteristics, treatment strategies, and follow-up outcomes of infantile Takayasu arteritis (TA) in the Chinese Han population.
methodsIn this retrospective study, we collected clinical data, Kerr scores (the NIH score), and arterial involvement scores (AIS) of infants diagnosed with TA at the time of initial diagnosis and at 1, 3, 6, and 12 months following initial treatment. Prognostic differences between various treatment groups were also analyzed.
resultsA total of 18 Chinese Han infants with TA were included. The average age of onset was 85.06 ± 54.64 days. The main clinical manifestations included fever (77.78%) and hypertension (55.56%). Both the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were elevated above normal. The average Kerr score was 3.28 ± 0.67, and the AIS was 10.67 ± 4.30. The most commonly affected arteries were the coronary arteries (72.22%) and the abdominal aorta (72.22%), with arterial wall thickening present in all patients (100%). All patients were initially diagnosed with bacterial infections, and 16 were specifically diagnosed with Kawasaki disease empirically. Ten patients received infliximab treatment, and eight were treated with tocilizumab. At 6 months post-treatment, both the AIS and Kerr scores showed significant improvement compared to initial values (t = 2.469, p = 0.019; t = 12.369, p = 0.000). No deaths occurred during the 12-month follow-up. No significant differences were observed between the tocilizumab and infliximab treatment groups.
conclusionITA is primarily characterized by fever and hypertension, along with elevated inflammatory biomarkers. The condition is easily diagnosed empirically with bacterial infections and Kawasaki disease, particularly in female infants around 3 months of age. Arterial involvement is often extensive and severe. Aggressive treatment within the first six months after diagnosis can significantly improve clinical outcomes. Both infliximab and tocilizumab demonstrated effective control of arterial inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.